House Panel: Defund Studies on Fetal Tissue Obtained from Abortions

The US House of Representatives “Select Investigative Panel” recommends that the NIH investigate fetal tissue research, and consider no longer funding certain types. 

By | January 9, 2017

WIKIMEDIA, DILIFFHouse Republicans on a special panel have renewed calls to defund the health care organization Planned Parenthood, and are now recommending that the National Institutes of Health (NIH) cut funding for some forms of fetal tissue research, Nature reported last week (January 3).

The panel—established in 2015 after videos surfaced of Planned Parenthood officials discussing how fetal tissue is gathered and purchased—recommended that the NIH commission studies to determine whether fetal tissue obtained from stillborn and preterm infants alone could meet the needs of the scientific community and, if so, that the agency phase out funding for tissue obtained from induced abortions.

“Scientific societies and universities have made misleading claims about fetal tissue research,” according to the report. “The Select Panel has received letters from 21 institutions. . . . In reality, not a single responding institution provided substantive evidence for the value of fetal tissue research.”

But experts maintain that fetal tissue obtained from abortions is vital to scientific research. Scientists note that fetal tissue has helped develop vaccines and innovative therapies, and 62 scientific organizations signed a statement in support of fetal tissue research in March 2016. “This report is wrong and wrongheaded,” Larry Goldstein, a neuroscientist at the University of California, San Diego, told Nature. “It’s driven by ideology, not science.”

The central thesis of the report is that it is unethical to obtain fetal tissue from induced abortions—especially if the practice does not benefit society. “In over 100 years of unrestricted clinical research, human fetal tissue has failed to provide a single medical treatment,” the committee wrote in its report. “Human fetal tissue is used for only 0.01% of the over 230 thousand FDA [US Food and Drug Administration]-approved clinical trials—and thus far, no trials using human fetal tissue have reported positive results for patients.”

But front-line therapies for rheumatoid arthritis, cystic fibrosis, and hemophilia were created using fetal tissue, Science reported. Meanwhile, some modern vaccines are propagated in MRC-5 and WI-38 cell lines, which were derived from fetuses aborted in the 1960s.  

The disconnect between scientists and the panel has some experts concerned about the future of science funding in the U.S. “This to me is very, very worrisome,” Alta Charo, an expert in law and ethics at the University of Wisconsin–Madison told Nature

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Paul Stein

Paul Stein

Posts: 205

January 9, 2017

The lesson here is for scientists to be watchful and very, very vocal in the defense of the research enterprise.  No more can the phrase "the science will speak for itself" be uttered from any responsible scientist.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham